Table Of Content

Ishii S, 1022 Lanziner A, 3S Michieletto M, 1132 Patterson JH, 85, 247, 257 Ito M, 1029 Lathers CM, 1 Migliau G, 1141 Paulos C, 610 Ito S, 42 Lausecker B, 1006 Min DI, 469 Pelliccia F, 1141 Izard M, 122 Lavelle J, 238 Mineyama Y, 540 Peters GR, 809 Lazarev A, 345 Mis SM, 1100 Peters J, 715 Jahnchen E, 414 le Coz F, 216 Misiti J, 462 Petryk L, 911 Jamali F, 760 Lee C-B, 422 Mistry G, 799 Pezzani M, 610 James LP, 48 Lee H-C, 469 Miyazaki M, 1029 Phillips K, 325 Jann MW, 963 Lee Y-S, 422 Mochon M, 580 Pieniaszek HJ Jr, 1161 Jensen B, 799 Leese PT, 720 Moesker HL, 639 Piepho RW, 573 Jezequel S, 216 Leeuwenkamp OR, 639 Mojaverian P, 923 Piergies AA, 187 Johnson DH, 760 Lefer AM, 365 Monroe §S, 315 Pinquier J-L, 72 Johnston J, 144 Lehmann DF, 1149 Montuenga C, 748 Poli A, 823 Jonkman JHG, 639 Leising G, 3S Mori Y, 1022 Polinsky MS, 580 Jorkasky D, 187 Lemon E, 832 Mobius H-J, 428 Pooler PM, 365 Jorkasky DK, 732 Lennartz H, 1114 Méllmann H, 938 Posvar E, 414 Juang D-J, 963 Lesesne HR, 206 Mroszczak E, 521 Posvar EL, 728 Jung D, 238 Letzig L, 48 Mulligan TE, 352, 654, Powell JR, 206 Jusko WJ, 874, 1100 Liao S, 1072 1006 Powell ML, 230 Lieberman R, 386 Murphy MG, 292 Poénicke K, 897 Kadobe Y, 439 Lim J, 634 Murray ED Jr, 540 Preston SL, 301 Kahan BD, 1100 Lin C-C, 634, 923 Prisant LM, 3, 867 Kahn J, 1107 Lin ET, 1012 Nakashima M, 439 Pritchard JF, 206 Kaiko RF, 595 Lin J, 292 Narjes H, 79 Puech AJ, 942 Kaiser BA, 580 Lin S-K, 963 Nayak RK, 884, 1072 Putnam K, 292 Kaltenbach ML, 1126 Lin T, 452 Nedelman JR, 452 Kamimura H, 1029 Liu CY, 1012 Neefe DL, 122 Quiggle DD, 540 Kamm 8, 332 Liu Y, 540 Nehmiz G, 79 Kano K, 168 Locke C, 1169 Neri DF, 1051 Kantoci D, 500, 540 Longstreth J, 25 Neub M, 414 Raasch R, 85 Kaplan LD, 55 Looby M, 897 Newman M, 55 Radulovic LL, 728 Karam JH, 1012 Lon F, 117 Nezamis J, 923 Radwanski E, 923 Karim A, 490, 985 Lowenthal DT, 823 Nicholls A, 315 Rahlfs VW, 33S Karol MD, 1064 Luderer J, 187 Nomeir A, 634 Rakhit A, 659 Kausal DJ, 386 Lum B, 580 Nomeir AA, 923 Rakhit AK, 799 Kazierad DJ, 720 Liicker PW, 610 Northfelt DW, 55 Rault RM, 144 Kearns GL, 48, 112, 397, Nuss C, 365 Reboldi G, 223 1051 Mackie AE, 938 Reder RF, 595 Keefe DL, 383 Maeda A, 1022 O’Conner M, 1012 Reele S, 187 Kikuchi K, 1029 Magni G, 1141 O’Connor R, 911 Regazzi MB, 117 Kimura R, 1022 Maines P, 814 Ogata H, 1022 Reidenberg P, 634 Klamerus KJ, 122, 720 Mak M, 1107 Ohashi K, 271, 892 Resel R, 3S Kluger J, 720 Maniara WM, 230 Ohashi K-I, 409 Reynolds R, 144 Koda J, 13 Manning SC, 832 Ohashi Y, 477 Richens A, 242 Koiso K, 1029 Mario L, 1132 Ohba S, 1029 Richter K, 311 Kolterman OG, 13 Marshall JD, 48 Ohmori M, 271 Riefler JF, 452 Koren G, 42 Martin DE, 85 Olson NZ, 595 Ring B, 1154 Korth-Bradley JM, 715 Martin FJ, 55 O’Rangers E, 122 Ripley E, 131 Kosoglou T, 923 Maserati R, 117 O’Rangers EA, 720 Ritschel WA, 610 Koss-Twardy SG, 152, 647, Massey KL, 760 Osborne B, 462 Rivera J, 595 659 Matsumoto Y, 168 Otsuka N, 1022 Robbins BA, 452 Kosuge K, 439 Matsushima H, 1029 Owen CS, 365 Roberts DW, 397 Kotegawa T, 409 Mattson CN, 247, 257 Robinson CA, 1161 Kradjan W, 189 Matzke GR, 144 Padhi ID, 35 Rocha C, 521 Kramer WG, 265 Mauleén D, 505 Page RC, 230 Rochdi M, 874 Krepostman A, 35 Mayer JM, 27S Pai S, 634 Rohatagi S, 311, 938 Kroh UF, 1114 Mazer NA, 732 Palatini P, 1132 Rooney M, 760 Ku Y-M, 469 McCracken JD, 540 Palmer M, 1072 Rose GM, 715 Kudo T, 168 Meehan JW, 634 Palumbo B, 823 Rosen RC, 814 Kulkarni GD, 814 Meibohm B, 938 Parker G, 332 Rosenzweig P, 72, 216 Kumagai Y, 409, 892 Meikle AW, 732 Parker VD, 175 Rosin M, 760 Kwong M, 1107 Melia AT, 152, 352, 647, Parkinson SJ, 365 Rotllan E, 505 654, 659, 1006 Parnetti L, 823 Rudis MI, 35 Lam YWF, 963 Meligeni JA, 452 Passe SM, 659 Russell J, 55 Landriault H, 903 Melillo G, 1141 Patat A, 216, 942 Ryan SV, 365 Landzberg BR, 559 Mensah GA, 867 Patel IH, 152 Ryo UY, 230 Sadowski JA, 659 Smith IL, 462 Trout JR, 814 Wechter WJ, 485, 500, Samaniego MD, 931 Smith WB, 265 Troy SM, 175 540, 546, 1S Samara EE, 1169 Smithers JA, 623 Tsina I, 521 Wei F-C, 963 Sambol NC, 1012 Sollie FAE, 639 Weingartner H, 292 Sandefer EP, 230 Songer SS, 206 Uchida Y, 168 Weiss M, 897 Santeusanio F, 823 Spencer GA, 696 Uematsu T, 439 Wells TG, 48 Sasaki M, 403, 892 Spénard J, 903 Ujhelyi MR, 122 Wetzelsberger KM, 610 Schachtel BP, 1120 Stalla-Bourdillon A, 72 Ullrich V, 16S Whitfield LR, 242, 604, Schaible H-G, 513 Steinman GL, 187 Uprichard ACG, 623 728 Scheel PJ, 931 Stelzer F, 3S Whitney EJ, 696 Urae A, 1022 Scheel PJ Jr, 707 Stimpel M, 701 Widner PJ, 1161 Urae R, 1022 Scherrmann J-M, 874 Stoeckel K, 1114 Wirebaugh S, 696 Schmider J, 783, 792 Straka RJ, 587, 740, 771 Witchwoot S, 546 Schmith VD, 247, 257 Sturgill MG, 814 Vadiei K, 122, 720 Wolkowitz OM, 292 Schran HF, 911 Sudoh T, 203 Valentine JL, 1051 Wong FA, 462 Sedman A, 187 Sueyoshi T, 1029 van Brummelen P, 799 Working P, 55 Sedman AJ, 242, 356, 604, Suh JT, 587 van Lier HJJ, 198 Wortham DC, 345 728, 998 Sun JX, 230 Vashi V, 325 Wright CE, 783 Segal JL, 64 Sunaga K-I, 203, 403 Venitz J, 1039 Wrighton S, 1154 Seibold JR, 292, 814 Sunshine A, 595 Vestal RE, 286 Senin U, 823 Suri A, 1126 Viger-Chougnet A, 1006 Xing J-J, 931 Serpas T. 265 Svensson CK, 35 Villani P, 117 Shader RI, 783, 792 Swigar M, 292 Vitow C, 462 Yang B-B, 356, 623, 998 Shappell SA, 1051 Volberding PA, 55 Young J, 521 Shen J, 85 Taddio A, 42 von Moltke LL, 783, 792 Yu A, 98 Shi J, 131 Takahashi K, 168 Yukawa E, 752 Shiga T, 409 Tam Y, 521 Waldman SA, 365, 462 Shimodaira H, 168 Tarnowski T, 521 Walker PF, 740 Zariffa N, 732 Shum L, 1161 Tauber U, 311 Walker SA, 884 Zarowitz BJ, 35 Sica DA, 131 Thoden WR, 1120 Walter B, 230 Zhang J, 292 Sides G, 1154 Thomas TJ, 814 Wang K, 1006 Zhi J, 152, 352, 647, 654, Sides GD, 832 Thomson D, 760 Ware JA, 35 659, 1006 Sinisi F, 1132 Timm U, 799 Warot D, 942 Zieleniuk I, 216, 942 Skurk C, 365 Tisdale JE, 35 Watanabe T, 1029 Zimmerman JJ, 122, 720, Slattum PW, 1039 Tomlinson B, 422 Watkins VS, 832 1100 Smith A, 274 Trapnell CB, 238 Webb CR, 35 Zipprich B, 897 Smith CM, 683 Trenk D, 414 Webster PA, 397 Zou M, 16S Subject Index, Volume 36 (1996) AC137 amifostine-induced hypotension, 365 mizolastine inhibition of histamine-induced skin pharmacokinetics, 13 angiotensin-converting enzyme inhibition effects wheal and flare, 72 ACEA 1021 on bronchial responsiveness, 361 new immunosuppressant drugs for organ trans- pharmacokinetics, A860 vesnarinone-induced granulocytopenia, 477 plantation, 1081 Acebutolol Age. See also Geriatrics; Pediatrics Alprostadil overdose treated with hemodialysis and extracor- atorvastatin pharmacokinetics, 242 pharmacokinetics, A851 poreal membrane oxygenation, 760 valaciclovir for herpes zoster, A853 Altitude Acetaminophen AIDS. See also Human Immunodeficiency Virus meperidine pharmacokinetics after short- and safety profile, A857 doxorubicin encapsulated in liposomes con- long-term exposure to high altitude, 610 for tension-type headache, 1120 taining surface-bound polyethylene glycol for American Board of Clinical Pharmacology toxicity in children, antigenic marker for, 397 AIDS-related Kaposi’s sarcoma, 55 N-Acetyltransferase Albuminuria announcement from, 285 slow acetylators of N-acetyltransferase in Hmong dihydropyridine calcium antagonist effects on al- Amifostine population residing in United States, 740 buminuria in diabetes, 280 hypotensive mechanisms of, 365 Acquired Immunodeficiency Syndrome. See Albuterol Amino-Methyl-Isoxazole-Propionic Acid AIDS; Human Immunodeficiency Virus optically active isomers, A488 lack of modulation of responses to nonsteroidal Adrenergic Activity Allergy and Immunology antiinflammatory drugs in rats, 20S cardiac imaging method for evaluating, A856 cortisol reduction after fluticasone propionate, Amiodarone sympathetic vasoconstriction mediation by a,- 938 pharmacokinetics, 122, 715, A862 and a@,-adrenoreceptors, A63 E25 reduction of IgE levels in adolescents and Anabolic Steroids B-Adrenergic Receptor Blockers children with moderate to severe allergic cardiovascular effects in weight-trained subjects, in blacks, 867 asthma, A859 1132 Adverse Effects lymphocyte interleukin-2 receptor inhibition by Analgesia acebutolol overdose treated with hemodialysis glucocorticoids, cyclosporine, or both, 931 estimation of onset, A855 and extracorporeal membrane oxygenation, lymphocyte responsiveness to glucocorticoids, ibuprofen pharmacokinetics and pharmacody- 760 cyclosporine, or both, 707 namics, A856 insulin-like growth factor I and expression of its Bronchial Responsiveness tirilazad and U-89678 pharmacokinetics in isch- receptors in rat spinal cord, A855 angiotensin-converting enzyme inhibition effects emic stroke, 809 ketoprofen and aspirin compared for postopera- on, 361 UP 269-6/digoxin interaction, A855 tive dental pain, A857 Budesonide B-Carotene oxycodone efficacy in postoperative pain, 595 pharmacodynamics, A864 interaction with orlistat, 152 paracetamol formulations, onset compared, pharmacokinetics, A864 pharmacokinetics, 152 A855 Buspirone Case Reports Anemia interaction with haloperidol, 951 presentation and publication of, 573 circadian rhythms in sickle cell vasoocclusive Cefaclor crisis, pain presentation and response to ketor- Calcium pharmacodynamics, A849 olac and meperidine, A864 dihydropyridine antagonists of, effects on albu- fixime Angina minuria in diabetes, 280 pharmacodynamics, A849 nitrate potentiation by ACE inhibitors in chronic role in metronidazole-induced neuromuscular Ceftibuten stable angina, A847 depression, A864 pharmacodynamics, A849 Angiotensin Antagonists Cancer Ceftriaxone losartan for management of hypertension, 3 doxorubicin encapsulated in liposomes con- pharmacokinetics, 1114 Angiotensin-Converting Enzyme Inhibitors taining surface-bound polyethylene glycol for Cefuroxime Axetil bronchial responsiveness effects of, 361 AIDS-related Kaposi’s sarcoma, 55 pharmacodynamics, A849 interaction with nitrates, A847 fluconazole pharmacokinetics in hematologic Central Nervous System. See also Psychophar- left ventricular geometric patterns in essential malignancies, A848 macology hypertension and, 1141 losoxantrone and taxol pharmacokinetics in re- assessment of response to dextroamphetamine, Antacids. See also specific antacids fractory malignancies, A858 1039 clopidogrel bioavailability, A856 Carbamazepine dextroamphetamine _chronopharmacokinetics Anticoagulant Drugs. See also specific anticoag- drug interaction detection by multiple peak ap- and chronopharmacodynamics, 1051 ulant drugs proach screening using routine clinical phar- physostigmine effects on scopolamine induced enhancement ofa nticoagulant effect by warfarin- macokinetic data, 752 sedation, A856 benzbromarone interaction, 168 Cardiovascular System. See also Congestive CGP 36 742 Antifungal Agents, Azole Heart Failure; Hypertension pharmacokinetics, 428 inhibition of midazolam hydroxylation by liver ACE inhibitor effects on left ventricular geomet- CGP 43371 microsomes in vitro, 783 ric patterns in essential hypertension, 1141 pharmacokinetics, 230 Antipyrine amifostine-induced hypotension, 365 Children. See Pediatrics interaction with atorvastatin, 356 amiodarone pharmacokinetics in impaired left Chiral Pharmacology Aspirin ventricular function, 720 albuterol optically active isomers, A488 interaction with meloxicam, 79 amiodarone pharmacokinetics in refractory ven- dexibuprofen double-blind randomized studies, for postoperative dental pain, A857 tricular tachycardia/fibrillation, 715 33S Asthma anabolic steroid effects in weight-trained sub- dexibuprofen physical aspects, 35 E25 reduction of IgE levels in adolescents and jects, 1132 enantiomer-specific assays, A489 children, A859 antihypertensive effectiveness of moexipril or enantioselective assays in comparative bioavail- pulmonary airway resistance and cardiovascular verapamil with hydrochlorothiazide, 701 ability studies of racemic drug formulations, changes in genetically prone “asthmatic rats,” cardiac imaging method for evaluating adrener- 490 A848 gic activity, A856 flurbiprofen. See Flurbiprofen Atorvastatin dihydropyridine calcium antagonist effects on al- ibuprofen enantiomers and lipid metabolism, interaction with antipyrine, 356 buminuria in diabetes, 280 27S pharmacodynamics, 604 drug monitoring with echocardiography, A861 inhibition of cyclooxygenase 1 and 2 by R(—) and pharmacokinetics, 242, 604, 728 eprosartan effects in warfarin anticoagulant ac- S(+) ibuprofen, 16S Azole Antifungal Agents tivity, A849 inversion half-lives of aryl propionic acid class inhibition of midazolam hydroxylation by liver furosemide lack of direct venodilatory effect in nonsteroidal antiinflammatory drugs, 500 microsomes in vitro, 783 healthy human subjects, 271 ketorolac kinetics and dynamics, A489, 521 gemfibrozil and niacin combination effect on nonsteroidal antiinflammatory drug R-enanti- lipid levels, 696 omer effects on gastrointestinal permeability, BAY x 1005 ifetroban interaction with warfarin in venous A488 interaction with theophylline, 639 thrombosis, A854 nonsteroidal antiinflammatory drugs modulation Befloxatone medicinal leeches for phlegmasia cerulea dolens of responses to N-methyl-D-aspartate, but not pharmacodynamics, 216 treatment, A850 substance P and amino-methyl-isoxazole-pro- pharmacokinetics, 216 nicorandil for ischemic heart disease, 559 pionic acid in rats, 20S psychomotor function and memory effects of, nitrate potentiation by ACE inhibitors in chronic racemic ibuprofen physical aspects, 3S 942 stable angina, A847 S(+) ibuprofen, 1S Benzbromarone noncompliance with isosorbide dinitrate treat- stereoselective inhibition of inducible cyclooxy- interaction with warfarin, 168 ment in ischemic heart disease, 587 genase by chiral nonsteroidal antiinflamma- Bile Acid Sequestrants paroxetine effects on terfenadine safety and PK, tory drugs, 505 7a-hydroxy-4-cholesten-3-one as early clinical A849 Cholesterol surrogate marker for LDL-cholesterol reduc- pravastatin and squalene alone and in combina- elevated levels of, therapy for, 189 tion following, A853 tion, in elderly patients with hypercholesterol- 7a-hydroxy-4-cholesten-3-one as early clinical Bioavailability. See Pharmacokinetics emia, 422 surrogate marker for LDL-cholesterol reduc- Blacks procainamide pharmacokinetics and pharmaco- tion following bile acid sequestrants, A853 #-adrenergic receptor blockers in, 867 dynamics in ventricular premature depolariza- pravastatin and squalene alone and in combina- Blood Pressure. See Hypertension; Hypotension tion, 623 tion, in elderly patients with hypercholesterol- Bone Marrow Transplantation pulmonary airway resistance and cardiovascular emia, 422 mesna and dimesna pharmacokinetics, A848 changes in genetically prone “asthmatic rats,” pravastatin effects in elderly hypertensive hyper- Book Reviews A848 cholesterolemic patients, A852 Neurotherapeutics: Emerging Strategies, 374 quinaprilat and quinapril pharmacokinetics and Oral Cephalosporins, 374 pharmacodynamics compared, 414 Chronopharmacology The Peroxisome: A Vital Organelle, 374 S-1452 pharmacokinetics and effect on platelet blood lymphocyte count modulation by circa- Pharmaceutical Powder Compaction Technol- aggregation, 409 dian rhythm of cortisol, A853 ogy, 374 sympathetic vasoconstriction mediation by a,- circadian rhythms in sickle cell vasoocclusive Quality of Life and Pharmacoeconomics in Clini- and a@,-adrenoreceptors, A63 crisis, pain presentation and response to ketor- cal Trials, Second Edition, 374 terfenadine systemic bioavailability and cardiac olac and meperidine and, A864 Breast Milk repolarization alteration by grapefruit juice, dextroamphetamine chronopharmacokinetics fluoxetine and norfluoxetine excretion in, 42 345 and chronophermacodynamics, 1051 lack of diurnal variation in glomerular filtration chronopharmacokinetics and chronopharmaco- ifetroban and Mylanta, A854 rates in elderly, 203 dynamics, 1051 ifetroban and ranitidine, A854 Cimetidine Diabetes Mellitus ifetroban and warfarin, A854 interaction with letrozole, A852 AC 137 pharmacokinetics after intravenous bolus ketoconazole and levocabastine, A847 interaction with meloxicam, 79 and infusion doses in patients with insulin- lamotrigine and felbamate, 634 Circadian Rhythms. See Chronopharmacology dependent diabetes, 13 lansoprazole and prednisone, 1064 Clemastine dihydropyridine calcium antagonist effects on al- letrozole and cimetidine, A852 pharmacokinetics, 911 buminuria in, 280 levocabastine and erythromycin, A847 Clinical Pharmacology GLP-1(7-37)(G) effects on blood glucose levels in levocabastine and ketoconazole, A847 present status and projections for future, 286 NIDDM, A63 levofloxacin and warfarin, 1072 responsibility for, 383 glyburide pharmacodynamics, lack of effect of lisinopril and diltiazem, A852 Clinical Trials eprosartan on, A849 lithium and neuroleptics, 951 crossover trials with binary response, 198 metformin pharmacokinetics and pharmacody- lithium and venlafaxine, 175 first-time-in-man studies, 187 namics in NIDDM, 1012 Maalox and meloxicam, 79 ganoxolone, A858 Digoxin meloxicam and cimetidine, Maalox, or aspirin, noncompliance as bane of, 674 interaction with erythromycin, A848 79 Clonidine interaction with nefazodone, 160 Mylanta and ifetroban, A854 pharmacokinetics, 892 interaction with UP 269-6, A855 nefazodone and digoxin, 160 Clopidogrel pharmacokinetics, 247, A855 nefazodone and phenytoin, A850 pharmacokinetics, A856 Dihydropyridine Calcium Antagonists neuroleptics and lithium, 951 tolerance and pharmacological activity, A861 effects on albuminuria in diabetes, 280 nifedipine and orlistat, 352 Codeine Diltiazem nitrates and ACE inhibitors, A847 pharmacodynamics, 1126 interaction with lisinopril, A852 ofloxacin and procainamide, 85 Cognitive Function Dimesna omeprazole and prednisone, 1064 physostigmine effects on scopolamine induced pharmacokinetics, A848 orlistat and G-carotene, 152 sedation, A856 Dirithromycin orlistat and nifedipine, 352 Colchicine interaction with terfenadine, 1154 orlistat and phenytoin, 654 pharmacokinetics, 874 tonsillar tissue penetration, 832 orlistat and vitamins A and E, 647 Congestive Heart Failure Dolasetron Mesylate orlistat and warfarin, 659 epoprostenol effects on digoxin pharmacokinet- pharmacokinetics, 903 paroxetine and terfenadine, A849 ics in, 247 Dopamine phenytoin and nefazodone, A850 epoprostenol effects on furosemide pharmacoki- inhibition of D, receptor-mediated behaviors in phenytoin and orlistat, 654 netics in, 257 mice by plasmid vector producing D, dopa- physostigmine and scopolamine, A856 evolving concepts in management of, 973 mine receptor antisense RNA, A862 prednisolone and sirolimus, 1100 procainamide pharmacokinetics in, 35 phentolamine for prevention of tissue injury in- prednisone and lansoprazole, 1064 smoking effects on theophylline deposition in duced by, A851 prednisone and omeprazole, 1064 hepatic disease and congestive heart failure, Doxazosin ranitidine and ifetroban, A854 A862 pharmacokinetics, 325 scopolamine and physostigmine, A856 torsemide pharmacodynamics, 265 Doxorubicin sirolimus and prednisolone, 1100 Corticosteroids doxorubicin encapsulated in liposomes con- terazosin and finasteride, 1169 cortisol suppression as measure of systemic ef- taining surface-bound polyethylene glycol for terfenadine and dirithromycin, 1154 fect, A854 AIDS-related Kaposi’s sarcoma, 55 terfenadine and paroxetine, A849 Cortisol Drug Development. See also Clinical Trials theophylline and BAY x 1005, 639 blood lymphocyte count modulation by circa- first-time-in-man studies, 187 UP 269-6 and digoxin, A855 dian rhythm of, A853 role of academia, government, industry, and venlafaxine and lithium, 175 corticosteroid effect measured by cumulative CRO’s, 1 vitamins A and E and orlistat, 647 suppression of, A854 Drug-Induced Disease warfarin and benzbromarone, 168 fluocortolone suppression, 311 amifostine-induced hypotension, 365 warfarin and eprosartan, A849 reduction after fluticasone propionate, 938 calcium’s role in metronidazole-induced neuro- warfarin and ifetroban, A854 Cyclooxygenase muscular depression, A864 warfarin and levofloxacin, 1072 inhibition of cyclooxygenase 1 and 2 by R(—) and teaching healthcare professionals about, 386 warfarin and orlistat, 659 S(+) ibuprofen, 16S vesnarinone-induced granulocytopenia, 477 DUP 734 stereoselective inhibition of inducible cyclooxy- Drug Interactions pharmacokinetics, A850 genase by chiral nonsteroidal antiinflamma- ACE inhibitors and nitrates, A847 tory drugs, 505 antipyrine and atorvastatin, 356 Cyclosporine aspirin and meloxicam, 79 correlation of area under the curve and single atorvastatin and antipyrine, 356 E25 point trough level, A859 BAY xX 1005 and theophylline, 639 IgE level reduction in adolescents and children lymphocyte interleukin-2 receptor inhibition by benzbromarone and warfarin, 168 Echwiotcha rmdoidoegrraatpeh yt o severe allergic asthma, A859 glucocorticoids, cyclosporine, or both, 931 buspirone and haloperidol, 951 lymphocyte responsiveness to glucocorticoids, carbamazepine interaction detection by multiple dEdriutgo rmioalnsi toring with, A861 cyclosporine, or both, 707 peak approach screening using routine clinical Clinical Pharmacology and First-Time-in-Man pharmacokinetics, 580, A859 pharmacokinetic data, 752 Studies: The FDA Levels the Playing Field, 187 Cytochrome P450 B-carotene and orlistat, 152 fluoxetine and norfluoxetine inhibition of human cimetidine and letrozole, A852 Dissemination of Journal Reprints by a Pharma- cytochrome P450-3 A isoforms, in vivo and in cimetidine and meloxicam, 79 ceutical Company, 97 vilro, 792 digoxin and erythromycin, A848 Drug Development: Role of Academia, Govern- digoxin and nefazodone, 160 ment, Industry, and CRO’s, 1 digoxin and UP 269-6, A855 Efficacy Measures: Surrogates or Clinical Out- Dmaenttorcolloepnrea mide increase in bioavailability in ddiilrtiitahzreomm ycainnd lainsdi notperrifle, naAd8i5ne2, 1154 Ovecormveise?w, 7o6f 7 the ACCP Symposium on Chiral spinal cord injury, 64 : eprosartan and glyburide, A849 Pharmacology, Washington, DC, September Dermatomes eprosartan and warfarin, A849 23, 1995, 485 valaciclovir for herpes zoster, A853 erythromycin and digoxin, A848 Special Announcement from the American Board of Clinical Pharmacology, 285 Desethylamiodarone erythromycin and levocabastine, A847 Understanding the Chiral Pharmacology of Non- pharmacokinetics, A862 felbamate and lamotrigine, 634 steroidal Antiinflammatory Drugs in the Aryl Dextroamphetamine finasteride and terazosin, 1169 Propionic Acid Class: S(+) Ibuprofen, 1S assessment of central nervous system response glyburide and eprosartan, A849 Who is Responsible for Clinical Pharmacology?, to, 1039 haloperidol and buspirone, 951 383 1186 Education pseudoephedrine bioavailability, 923 terfenadine systemic bioavailability and cardiac case report presentation and publication, 573 verapamil pharmacokinetics and bioavailability, repolarization alteration by, 345 clinical geriatric psychopharmacology, 683 1022 computer-based system of learning in geriatric Fosinopril clinical pharmacology, A860 pharmacokinetics, A854 Haloperidol distance education, A63 Fosinoprilat interaction with buspirone, 951 emergency drug manual as teaching tool, A861 pharmacokinetics, A860 risperidone compared with, for phencyclidine teaching healthcare professionals about drug-in- Furosemide psychosis, A846 duced disease, 386 lack of direct venodilatory effect in healthy hu- Headache Elderly Patients. See Geriatrics man subjects, 271 tension type, ibuprofen and acetaminophen for, Electroencephalogram pharmacokinetics, 257 1120 physostigmine effects on scopolamine induced Heartburn sedation, A856 nizatidine for prevention of, A857 Enantioselective Assays GABA, Antagonists Hematology in comparative bioavailability studies of racemic CGP 36 742 pharmacokinetics, 428 fluconazole pharmacokinetics in hematologic drug formulations, 490 Ganciclovir malignancies, A848 Epidemiology pharmacokinetics, 238, 301 vesnarinone-induced granulocytopenia, 477 respiratory diseases in Nigeria, A846 Ganoxolone Hemodialysis sex differences in pharmacokinetics of ranitid- initial human experience, A858 acebutolol overdose treated with, 760 ine, 748 Gastrointestinal Tract nalmefine pharmacokinetics, 144 slow acetylators of N-acetyltransferase in Hmong flurbiprofen R-isomer effects on colonic cell pro- Hemofiltration population residing in United States, 740 liferation, A489 ceftriaxone pharmacokinetics in patients under- Eprosartan mechanism of enhancement of gastrointestinal going continuous veno—venous hemofiltra- interaction with glyburide, A849 toxicity of S-flurbiprofen by its enantiomer, tion, 1114 interaction with warfarin, A849 A489 Hepatic Function Erectile Dysfunction Mylanta or ranitidine effects on ifetroban phar- mycophenolate mofetil pharmacokinetics with alprostadil pharmacokinetics, A851 macokinetics, A854 varying degrees of hepatic oxidative impair- Erythromycin nizatidine for heartburn prevention, A857 ment, 332 interaction with digoxin, A848 nonsteroidal antiinflammatory drug R-enanti- ondansetron pharmacokinetics in hepatic insuf- 17B-Estradiol omer effects on gastrointestinal permeability, ficiency, 206 pharmacokinetics, 998 A488 smoking effects on theophylline deposition in Extracorporeal Membrane Oxygenation R-verapamil inhibition of talinolol intestinal se- hepatic disease and congestive heart failure, acebutolol overdose treated with, 760 cretion, A862 A862 Eye Gemfibrozil trapidil pharmacokinetics in liver disease, 897 timolol effects on ocular dynamics, A861 niacin combined with, effect on lipid levels, 696 Hepatitis Gender livomycin for, A63 Famotidine atorvastatin pharmacokinetics, 242 Herpes Simplex pharmacodynamics, 48 ranitidine pharmacokinetics, 748 valaciclovir for prevention of vesicular lesions in pharmacokinetics, 48 Geriatrics recurrent genital herpes, A853 Felbamate clinical geriatric psychopharmacology, 683 Herpes Zoster interaction with lamotrigine, 634 compuier-based system of learning in geriatric valaciclovir for, A853 Finasteride clinical pharmacology, A860 High Altitude interaction with terazosin, 1169 dolasetron mesylate pharmacokinetics, 903 meperidine pharmacokinetics after short- and First-Time-in-Man Studies fosinopril pharmacokinetics, A854 long-term exposure to, 610 FDA policy, 187 hydrochlorothiazide pharmacokinetics, A854 High-Performance Liquid Chromatography Flavanones lack of diurnal variation in glomerular filtration citric flavonone determination by, A852 citric, determination by HPLC, A852 rates in elderly, 203 Histamine Fluconazole posatirelin pharmacokinetics, 823 mizolastine inhibition of histamine-induced skin pharmacokinetics, A848 pravastatin and squalene alone and in combina- wheal and flare, 72 Fluocortolone tion, in elderly patients with hypercholesterol- Human Immunodeficiency Virus pharmacodynamics, 311 emia, 422 hydroxyurea pharmacokinetics in patients in- pharmacokinetics, 311 pravastatin effects in elderly hypertensive hyper- fected with, 117 Fluoxetine cholesterolemic patients, A852 oxidative metabolism and reductive capacity in excretion in human breast milk, 42 Glomerular Filtration Rate sulfonamide-tolerant and -intolerant patients, inhibition of human cytochrome P450-3 A iso- lack of diurnal variation in glomerular filtration 1149 forms by, in vivo and in vitro, 792 rates in elderly, 203 Hydrochlorothiazide inhibition of midazolam hydroxylation by liver GLP-1(7-37)(G) antihypertensive effectiveness in combination microsomes in vitro, 783 effects on blood glucose levels in NIDDM, A63 with moexipril, 701 Flurbiprofen Glucocorticoids pharmacokinetics, A854, A860 antinociceptive action of flurbiprofen enantiom- lymphocyte interleukin-2 receptor inhibition by Hydroxyurea ers, 513 glucocorticoids, cyclosporine, or both, 931 pharmacokinetics, 117 antiproliferative effects of flurbiprofen enantiom- lymphocyte responsiveness to glucocorticoids, Hypercholesterolemia ers, 540 cyclosporine, or both, 707 pravastatin and squalene alone and in combina- human plasma concentrations of R, S, and race- Glyburide tion, in elderly patients with, 422 mic flurbiprofen given as toothpaste, 546 interaction with eprosartan, A849 pravastatin effects in elderly hypertensive hyper- mechanism of enhancement of gastrointestinal pharmacodynamics, A849 cholesterolemic patients, A852 toxicity of S-flurbiprofen by its enantiomer, P-Glycoprotein Hyperinsulinemia A489 digoxin-erythromycin interaction as evidence for pravastatin effects in elderly hypertensive hyper- R-isomer effects on colonic cell proliferation, in vitro competition for, A848 cholesterolemic patients, A852 A489 a,-Glycoprotein Hypertension sites of action of R- and S-flurbiprofen, A488 tamsulosin hydrochloride pharmacokinetics in ACE inhibitor effects on left ventricular geomet- Fluticasone Propionate renal impairment, 1029 ric patterns in, 1141 cortisol reduction after, 938 Granulocyte-Macrophage Colony-Stimulating antihypertensive effectiveness of moexipril or Food Factor verapamil with hydrochlorothiazide, 701 clopidogrel bioavailability, A856 pharmacokinetics, 1107 chronopharmacologic considerations in treating, DUP 734 pharmacokinetic effects, A850 Granulocytopenia 771 ganciclovir bioavailability, 238 vesnarinone-induced, 477 diltiazem and lisinopril additive effects, A852 loratidine bioavailability, 923 Grapefruit Juice imidazoline receptor agonist therapy, 98 nizatidine for prevention of postprandial heart- quinidine pharmacokinetic and pharmacody- losartan for essential hypertension, 403 burn, A857 namic effects, 469 losartan therapy, 3 pravastatin effects in elderly hypertensive hyper- Ketorolac tacrolimus bioequivalence, A847 cholesterolemic patients, A852 chiral kinetics and dynamics, A489, 521 terfenadine systemic bioavailability and cardiac Hypogonadism circadian rhythms in sickle cell vasoocclusive repolarization alteration by grapefruit juice, testosterone pharmacokinetics, 732 crisis and, pain presentation and response to, Hypolipidemic Agents A864 Metformin CGP 43371 absorption explained by gamma scin- pharmacodynamics, 1012 tigraphy and pharmacokinetics, 230 pharmacokinetics, 1012 L-365,260 Methemoglobinemi Hypotension amifostine-induced, 365 pharmacokinetics, 292 after phenazopyridine overdose in an infant, 112 Lamotrigine N-MethyI-D-Aspartate interaction with felbamate, 634 Ibuprofen nonsteroidal antiinflammatory drugs modulation cyclooxygenase 1 and 2 inhibition by R(—) and Lansoprazole of responses to in rats, 20S S(+) ibuprofen, 16S Lineteecrhaecst ion with prednisone, 1064 Metoclopramide dexibuprofen double-blind randomized studies, dantrolene bioavailability in spinal cord injury dex3i3bS uprofen physical aspects, 3S Lfieomrfp ta pihVrelenedtg,rm iaacsumiliaao rd caerFrouunnlceeat ipodnho alremnasc otkrienaetmteincts, iAn8, 5702 0 Metinrcorneiadsaezdo lbey , 64 epnhaanrtmiaocmoedrysn aomf,i clsi,pi d Am8e5t6a bolism and, 27S Letrozole calbcy,i uAm 864in neuromuscular depression induced pharmacokinetics, A856 interaction with cimetidine, A852 Midazolam polysomnographic and subjective sleep measure Lpehvaorcmaacboaksitnientei cs, A852 hydroxylation by liver microsomes in vitro, inhi- effects, A859 bition by fluoxetine, norfluoxetine, and azole pseudoephedrine combined with, side effect pro- interaction with ketoconazole, A847 antifungal agents, 783 racfielmei co,f, pAh8y5s7i cal aspects, 3S Lpienhtvaeorrfmalacoctxoiaokcni innew tiitchs ,w arAf8a4r7in , 1072 Miinhziobliatsitoinn eo f histamine-induced skin wheal and S(+) ibuprofen chiral pharmacology, 1S flare by, 72 S(+) ibuprofen pharmacodynamics and pharma- Lipids. See also Cholesterol Moexipril cokinetics, 7S CGP 43371 absorption explained by gamma scin- antihypertensive effectiveness in combination for tension-type headache, 1120 tigraphy and pharmacokinetics, 230 with verapamil or hydrochlorothiazide, 701 Ifetroban gemfibrozil and niacin combination effect on lev- Monoamine Oxidase Inhibitors interaction with Mylanta, A854 els of, 696 befloxatone pharmacodynamics and pharmaco- interaction with ranitidine, A854 ibuprofen enantiomers and metabolism of, 27S kinetics, 216 interaction with warfarin, A854 Liinsteirnaocptriioln with diltiazem, A852 Monoclonal Antibodies pharmacokinetics, A854 Lithium E25 reduction of IgE levels in adolescents and Imidazoline Receptor Agonists children with moderate to severe allergic for hypertension, 98 iinntteerraaccttiioonn wwiitthh nveeunrloalfeapxtiinces,, 197551 asthma, A859 Immunology. See Allergy and Immunology M-5041T I ppressant Drugs. See also specific im- neurotoxicity in combination with neuroleptics, pharmacokinetics, 892 munosuppressant drugs A850 Mycophenolate Mofetil new, for organ transplantation, 1081 Livomycin pharmacokinetics, 325, 332 Infectious Diseases for hepatitis, A63 Mylanta dirithromycin tonsillar tissue penetration, 832 Loratidine interaction with ifetroban, A854 ibuprofen-pseudoephedrine combination side ef- pharmacokinetics, 923 fects in upper respiratory tract infection, A857 Losartan Nalmefine livomycin for hepatitis, A63 for essential hypertension, 403 pharmacokinetics, 144 vvIaanllsraauecclciiiuccnrll rooevvniitrr gffeoonrri tphareler vpehenesrt pizeoosns, t eorAf, 8 v5eA3s8 i5c3u lar lesions in LfpLoohyrasm rophmxyhaapocnecotryktrtieoennnesseti iocns, , 3 A858 NiNinneettufeerarrozaaloccettdpiiotoonnine c sww iitthh dpihgeonxyitno,i n,16 0A 850 praacvnhados,lt easAtt8ien5r 2o elfefemcitcs in pealtdieernltys , hypehrytpernisnisvuel ihnyepmeira- bilnotdoeidral ne ulrkyihmnyp-t2hh omc ryeotcfee pctoorctroi usnoitln ,h imAboi8td5iu3ol na tiboyn glbuyco ccoirrtcia-- Ninneetuuerrrooatlcotoxigioycn i tyw itihn cloimtbhiiunma,t i9o5n1 with lithium, A850 Insulin-Like Growth Factor I coids, cyclosporine, or both, 931 metoclopramide increase in bioavailability of analgesic action and expression of receptors in dantrolene in spinal cord injury, 64 rat spinal cord, A855 Maalox Neurotoxicity Interleukin-2 interaction with meloxicam, 79 lithium and neuroleptics in combination, A850 lymphocyte interleukin-2 receptor inhibition by Malignancies Niacin glucocorticoids, cyclosporine, or both, 931 doxorubicin encapsulated in liposomes con- gemfibrozil combined with, effect on lipid levels, Ischemic Heart Disease taining surface-bound polyethylene glycol for 696 nicorandil for, 559 AIDS-related Kaposi’s sarcoma, 55 Nicorandil noncompliance with isosorbide dinitrate treat- fluconazole pharmacokinetics in hematologic for ischemic heart disease, 559 ment in ischemic heart disease, 587 malignancies, A848 Nifedipine Isobutyramide losoxantrone and taxol! pharmacokinetics in re- interaction with orlistat, 352 pharmacokinetics, 617 fractory malignancies, A858 Nitrates Isosorbide Dinitrate Meloxicam interaction with ACE inhibitors, A847 noncompliance with isosorbide dinitrate treat- interaction with cimetidine, Maalox, or aspirin, Nizatidine ment in ischemic heart disease, 587 for heartburn prevention, A857 Meperidine Noncompliance Journal Reprints circadian rhythms in sickle cell vasoocclusive with isosorbide dinitrate treatment in ischemic dissemination by pharmaceutical company, 97 crisis and, pain presentation and response to, heart disease, 587 A864 as therapeutic dilemma and bane of clinical tri- Kaposi’s Sarcoma pharmacokinetics, 610 als, 674 doxorubicin encapsulated in liposomes con- Mesna Nonsteroidal Antiinflammatory Drugs. See also taining surface-bound polyethylene glycol for pharmacokinetics, A848 specific nonsteroidal antiinflammatory drugs AIDS-related Kaposi’s sarcoma, 55 Metabolism inversion half-lives of aryl propionic acid class Ketoconazole midazolam hydroxylation by liver microsomes nonsteroidal antiinflammatory drugs, 500 interaction with levocabastine, A847 in vitro, inhibition by fluoxetine, norfluoxe- modulation of responses to N-methyl-D-aspar- Ketoprofen tine, and azole antifungal agents, 783 tate, but not substance P and amino-methyl- for postoperative dental pain, A857 quinidine pharmacokinetics and pharmacody- isoxazole-propionic acid in rats, 20S safety profile, A857 namics, effects of grapefruit juice on, 469 nonsteroidal antiinflammatory drug R-enantiomer effects on gastrointestinal permeability, codeine, 1126 meperidine, 610 A488 dextroamphetamine — chronopharmacokinetics mesna, A848 stereoselective inhibition of inducible cyclooxy- and chronopharmacodynamics, 1051 metformin, 1012 genase by chiral nonsteroidal antiinflamma- famotidine, 48 mycophenolate mofetil, 325, 332 tory drugs, 505 finasteride-terazosin interaction, 1169 nalmefine, 144 Norfluoxetine fluocortolone, 311 nefazodone interaction with digoxin, 160 excretion in human breast milk, 42 glyburide, A849 nortriptyline, A851 inhibition of human cytochrome P450-3 A iso- ibuprofen, A856 ondansetron, 206 forms by, in vivo and in vitro, 792 ifetroban interaction with warfarin, A854 orlistat, 1006 inhibition of midazolam hydroxylation by liver metformin, 1012 oxaprozin, 985 microsomes in vitro, 783 nefazodone interaction with digoxin, 160 phenylpropanolamine, 911 Nortriptyline procainamide, 85, 623 phenytoin, A850 pharmacokinetics, A851 quinapril, 414 posatirelin, 823 quinaprilat, 414 prednisolone, 1100 Obesity quinidine, 469 procainamide, 35, 85, 623 orlistat metabolic profiles in, 1006 S(+) ibuprofen, 7S pseudoephedrine, 923 Ofloxacin tepoxalin, 462 quinapril, 414 interaction with procainamide, 85 terbinafine, 452 quinaprilat, 414 Omeprazole terfenadine, 1154 quinidine, 469 interaction with prednisone, 1064 torsemide, 265 ranitidine, 748 Oncology Pharmacoepidemiology retinoids, 799 doxorubicin encapsulated in liposomes con- respiratory diseases in Nigeria, A846 S-1452, 409 taining surface-bound polyethylene glycol for sex differences in pharmacokinetics of ranitid- sematilide, 131 AIDS-related Kaposi’s sarcoma, 55 ine, 748 S(+) ibuprofen, 7S fluconazole pharmacokinetics in hematologic slow acetylators of N-acetyltransferase in Hmong tamsulosin hydrochloride, 1029 malignancies, A848 population residing in United States, 740 taxol, A858 losoxantrone and taxol pharmacokinetics in re- Pharmacokinetics tepoxalin, 462 fractory malignancies, A858 AC 137, 13 terbinafine, 452 Ondansetron ACEA 1021, A860 terfenadine, 1154 pharmacokinetics, 206 alprostadil, A851 testosterone, 732 Organ Transplantation amiodarone, 122, 715, A862 tirilazad, 809 bone marrow, mesna and dimesna pharmacoki- atorvastatin, 242, 604, 728 topiramate, 884 netics, A848 befloxatone, 216 trapidil, 897 new immunosuppressant drugs, 1081 biological fluid preservation at ambient tempera- U-89678, 809 renal, cyclosporine pharmacokinetics in chil- tures, A860 UP 269-6, A855 dren following, 580 budesonide, A864 venlafaxine interaction with lithium, 175 renal, prednisolone pharmacokinetics during sir- carbamazepine interaction detection by multiple verapamil, 25, 1022 olimus administration, 1100 peak approach screening using routine clinical VX-366, 617 Orlistat pharmacokinetic data, 752 warfarin, 1072 interaction with G-carotene, 152 6-carotene, 152 Y-27152, 439 interaction with nifedipine, 352 ceftriaxone, 1114 yohimbine, 814 interaction with phenytoin, 654 CGP 36 742, 428 zalcitabine, A851 interaction with vitamins A and E, 647 CGP 43371, 230 Phenazopyridine interaction with warfarin, 659 clemastine, 911 methemoglobinemia after overdose in an infant, pharmacokinetics, 1006 clonidine, 892 112 Oxaprozin clopidogrel, A856 Phencyclidine Psychosis pharmacokinetics, 985 colchicine, 874 risperidone and haloperidol compared for, A846 Oxycodone cyclosporine, 580, A859 Phentolamine analgesic efficacy in postoperative pain, 595 desethylamiodarone, A862 for prevention of dopamine-induced tissue in- dextroamphetamine chronopharmacokinetics jury, A851 Paracetamol and chronopharmacodynamics, 1051 Phenylpropanolamine effervescent and noneffervescent formulations, digoxin, 247, A855 pharmacokinetics, 911 comparison of onset of analgesia, A855 dimesna, A848 Phenytoin Paroxetine dolasetron mesylate, 903 interaction with nefazodone, A850 interaction with terfenadine, A849 doxazosin, 325 interaction with orlistat, 654 Pediatrics DUP 734, A850 pharmacokinetics, A850 acetaminophen toxicity, antigenic marker for, enantioselective assays in comparative bioavail- Phlegmasia Cerulea Dolens 397 ability studies of racemic drug formulations, medicinal leeches in treatment of, A850 cyclosporine pharmacokinetics after renal trans- 490 Physostigmine plant, 580 17B-estradiol, 998 interaction with scopolamine, A856 E25 reduction of IgE levels in adolescents and famotidine, 48 Platelet Aggregation children with moderate to severe allergic finasteride-terazosin interaction, 1169 S-1452 effects on, 409 asthma, A859 fluconazole, A848 Posatirelin famotidine pharmacokinetics and pharmacody- fluocortolone, 311 pharmacokinetics, 823 namics in children, 48 fosinopril, A854 Potassium Channel Openers fluoxetine and norfluoxetine excretion in human fosinoprilat, A860 Y-27152 pharmacokinetics, 439 breast milk, 42 furosemide, 257 Pravastatin methemoglobinemia after phenazopyridine over- ganciclovir, 238, 301 beneficial effects on hyperinsulinemia in elderly dose in an infant, 112 granulocyte-macrophage colony-stimulating fac- hypertensive hypercholesterolemic patients, Pharmaceutical Companies tor, 1107 A852 journal reprint dissemination by, 97 hydrochlorothiazide, A854, A860 pravastatin and squalene alone and in combina- Pharmacodynamics hydroxyurea, 117 tion, in elderly patients with hypercholesterol- atorvastatin, 604 ibuprofen, A856 emia, 422 befloxatone, 216 Ifetroban, A854 Prednisolone budesonide, A864 L-365,260, 292 interaction with sirolimus, 1100 cefaclor, A849 letrozole, A852 pharmacokinetics, 1100 cefixime, A849 levocabastine, A847 Prednisone ceftibuten, A849 loratidine, 923 interaction with lansoprazole, 1064 cefuroxime axetil, A849 losoxantrone, A858 interaction with omeprazole, 1064 Procainamide S-1452 Theophylline interaction with ofloxacin, 85 pharmacokinetics, 409 interaction with BAY X 1005, 639 pharmacodynamics, 85, 623 platelet aggregation effects, 409 smoking effects on deposition in hepatic disease pharmacokinetics, 35, 85, 623 Schizophrenia and congestive heart failure, A862 Pseudoephedrine buspirone lack of interaction with haloperidol Therapeutic Effects ibuprofen combined with, side effect profile of, in, 951 classification of drug action based on, 669 A857 Scopolamine Thromboxane A, Receptor Antagonists pharmacokinetics, 923 interaction with physostigmine, A856 $01352 pharmacokinetics and effects on platelet Psychopharmacology Sedative-Hypnotics. See also specific sedative- aggregation, 409 befloxatone effects on psychomotor function and hypnotics Timolol memory, 942 comparative memory effects, A858 ocular dynamics after administration of, A861 buspirone lack of interaction with haloperidol in Sematilide Tirilazad schizophrenia, 951 pharmacokinetics, 131 pharmacokinetics, 809 geriatric, 683 Sex Differences Topiramate risperidone and haloperidol compared for phen- atorvastatin pharmacokinetics, 242 pharmacokinetics, 884 cyclidine psychosis, A846 ranitidine pharmacokinetics, 748 Torsemide Sickle Cell Anemia pharmacodynamics, 265 Quinapril circadian rhythms in vasoocclusive crisis in, Trapidil pharmacodynamics, 414 pain presentation and response to ketorolac pharmacokinetics, 897 pharmacokinetics, 414 and meperidine and, A864 Quinaprilat Sirolimus pharmacodynamics, 414 interaction with prednisolone, 1100 U-89678 pharmacokinetics, 414 Sleep pharmacokinetics, 809 Quinidine ibuprofen effects on polysomnographic and sub- UP 269-6 pharmacodynamics, 469 jective measures of, A859 interaction with digoxin, A855 pharmacokinetics, 469 Smoking pharmacokinetics, A855 theophylline deposition in hepatic disease and Racemic Drug Formulations congestive heart failure, A862 enantioselective assays in comparative bioavail- Squalene Valaciclovir for genital herpes, A853 ability studies of, 490 pravastatin and squalene alone and in combina- human plasma concentrations of R, S, and race- tion, in elderly patients with hypercholesterol- Venlafaxine mic flurbiprofen given as toothpaste, 546 emia, 422 interaction with lithium, 175 Ranitidine Steroids. See also specific steroids Venous Thrombosis interaction with ifetroban, A854 anabolic, cardiovascular effects in weight- ifetroban interaction with warfarin, A854 pharmacokinetics, 748 trained subjects, 1132 Ventricular Premature Depolarization Renal Function cortisol suppression as measure of systemic ef- procainamide pharmacokinetics and pharmaco- amiodarone disposition with normal and im- fect of corticosteroids, A854 dynamics in, 623 paired renal function, 122 lymphocyte interleukin-2 receptor inhibition by Ventricular Tachycardia/Fibrillation early cytoskeletal changes in rat brain during glucocorticoids, cyclosporine, or both, 931 amiodarone pharmacokinetics in, 715 acute renal failure, A858 lymphocyte responsiveness to glucocorticoids, Verapamil fosinoprilat and hydrochlorothiazide pharmaco- cyclosporine, or both, 707 antihypertensive effectiveness in combination kinetics in subjects with and without renal im- Stroke with moexipril, 701 pharmacokinetics, 25, 1022 pairment, A860 tirilazad and U-89678 pharmacokinetics in isch- impaired, effect on zalcitabine pharmacokinet- emic stroke, 809 R-verapamil inhibition of talinolol intestinal se- ics, A851 Substance P cretion, A862 lack of diurnal variation in glomerular filtration nonsteroidal antiinflammatory drugs lack of Vesnarinone rates in elderly, 203 modulation of responses to in rats, 20S granulocytopenia induced by, 477 nalmefine pharmacokinetics in renal insuffi- Sulfonamide Vitamins ciency and hemodialysis, 144 oxidative metabolism and reductive capacity in antioxidant vitamins and health, 1093 sematilide pharmacokinetics in renal failure, 131 human immunodeficiency virus positive pa- retinoid pharmacokinetics after vitamin A, 799 tamsulosin hydrochloride pharmacokinetics in tients, 1149 vitamin A interaction with orlistat, 647 renal impairment, 1029 vitamin E interaction with orlistat, 647 VX-366 Renal Transplantation Tacrolimus pharmacokinetics, 617 cyclosporine pharmacokinetics in children fol- bioequivalence, A847 lowing, 580 Talinolol prednisolone pharmacokinetics during sirolimus R-verapamil inhibition of intestinal secretion of, Warfarin administration, 1100 A862 interaction with benzbromarone, 168 Respiratory Diseases Tamsulosin Hydrochloride interaction with eprosartan, A849 epidemiology and pharmacotherapeutic manage- pharmacokinetics, 1029 interaction with ifetroban, A854 ment in Nigeria, A846 Taxol interaction with levofloxacin, 1072 E25 reduction of IgE levels in adolescents and pharmacokinetics, A858 interaction with orlistat, 659 children, in asthma, A859 Tepoxalin pharmacokinetics, 1072 ibuprofen-pseudoephedrine combination side ef- pharmacodynamics, 462 fects in upper respiratory tract infection, A857 pharmacokinetics, 462 pulmonary airway resistance and cardiovascular Terazosin Y-27152 changes in genetically prone ‘asthmatic rats,” interaction with finasteride, 1169 pharmacokinetics, 439 A848 Terbinafine Yohimbine Retinoids pharmacodynamics, 452 pharmacokinetics, 814 pharmacokinetics, 799 pharmacokinetics, 452 Risperidone Terfenadine haloperidol compared with, for phencyclidine interaction with dirithromycin, 1154 Zalcitabine psychosis, A846 interaction with paroxetine, A849 pharmacokinetics, A851 RNA pharmacodynamics, 1154 Zidovudine inhibition of D, receptor-mediated behaviors in pharmacokinetics, 1154 recombinant human granulocyte-macrophage mice by plasmid vector producing D. dopa- Testosterone colony-stimulating factor pharmacokinetics, mine receptor antisense RNA, A862 pharmacokinetics, 732 1107 - : tthe oe <Z { ° ‘ a; y ; : . : oo ‘ ; 4 ; th es poomerarne near Sar * eo auae : R : : . ‘ : 3. 4 s: j ° ;o e . ¢ . ° ‘ be - \ : ; : a 2 5 : 7 : 3 ; -. . .o > . . 4 ~ . ater, : ‘ °- ' 2 : -a = . 4 C4 ° 7, A ’4 7 ' a1 s e ‘ 42 : 7 .: . :